Clinical trials: Stage IIIB Non-small Cell Lung Cancer
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Carcinoma, Non-Small-Cell Lung
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
The purpose of the study was to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a…
- Trial name
- GeoMETry-III (NCT04427072)
- Testing
- Capmatinib, Docetaxel
- Where
- 43 sites in Belgium, Brazil and 16 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00454194
- Testing
- pemetrexed disodium, sorafenib tosylate
- Where
- 207 sites in United States
- Volunteers
- 110 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Febrile Neutropenia, Stage 0 Breast Cancer
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia.
- Conditions
- Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer
- Trial name
- TrACER (NCT02728596)
- Testing
- Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 160 sites in United States, Puerto Rico
- Volunteers
- 3,665 people
- Sponsor
- SWOG Cancer Research Network
Carcinoma, Non-Small-Cell Lung
Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.
- Trial name
- NCT03102242
- Testing
- Atezolizumab
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Alliance Foundation Trials, LLC.
Carcinoma, Non-Small-Cell Lung
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study.
- Trial name
- NCT04585815
- Testing
- Sasanlimab Prefilled syringe, Encorafenib, Binimetinib
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with…
- Trial name
- NCT03285321
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Greg Durm, MD
Lung Cancer
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Trial name
- NCT00661193
- Testing
- carboplatin, erlotinib hydrochloride, paclitaxel
- Where
- 124 sites in United States
- Volunteers
- 59 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
This randomized phase III trial studies pemetrexed disodium to see how well it works compared with erlotinib hydrochloride as second-line therapy in treating patients with non-small cell lung cancer that has spread to other…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- MARVEL (NCT00738881)
- Testing
- Erlotinib Hydrochloride, Pemetrexed Disodium
- Where
- 269 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Maintenance treatment of advanced stage squamous cell NSCLC. Phase III, randomized, open-label, multi-center study of nab-paclitaxel with best supportive care (BSC) or BSC alone as maintenance treatment after response or stable…
- Trial name
- NCT02027428
- Testing
- Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance)
- Where
- 119 sites in United States, Germany and 3 more
- Volunteers
- 427 people
- Sponsor
- Celgene
Non-small Cell Lung Cancer
A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This is a multicenter, multinational, double-blind, 1:1 randomized, parallel-group, equivalence Phase 3 study to compare the efficacy and safety of MB02 plus chemotherapy (carboplatin and paclitaxel) versus Avastin® plus…
- Trial name
- STELLA (NCT03296163)
- Testing
- MB02 (Bevacizumab Biosimilar Drug), EU-approved Avastin®, Carboplatin
- Where
- 118 sites in Brazil, Bulgaria and 16 more
- Volunteers
- 627 people
- Sponsor
- mAbxience Research S.L.
Carcinoma, Non-Small-Cell Lung
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma…
- Trial name
- NCT02231164
- Testing
- docetaxel, nintedanib
- Where
- 13 sites in United States, Georgia and 1 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study will provide treatment with erlotinib to participants with advanced NSCLC who have received at least one course of standard chemotherapy or radiation therapy, or who are not medically suitable for either.
- Trial name
- NCT00949910
- Testing
- Erlotinib
- Where
- 543 sites in Albania, Argentina and 49 more
- Volunteers
- 6,586 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)
The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.
- Trial name
- NCT00979576
- Testing
- BIBF 1120 M + Pemetrexed, BIBF 1120 H + Pemetrexed, BIBF 1120 RD + Pemetrexed
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
Phase II Iressa & Carbo/Gem in NSCLC
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.
- Trial name
- NCT00264498
- Testing
- Gefitinib, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC
This is an open-label, single institution, phase II study of Sorafenib in combination with docetaxel and carboplatin in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00647426
- Testing
- Sorafenib + Docetaxel/Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non Small Cell Lung Carcinoma
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
The main purpose of this research study is to see if adding fulvestrant (Faslodex) to erlotinib (Tarceva) is effective in patients with stage IIIb/IV Non-Small Cell Lung Cancer.
- Trial name
- NCT00592007
- Testing
- Fulvestrant and Erlotinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Lyudmila Bazhenova, M.D.
Lung Cancer
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00970684
- Testing
- bevacizumab, docetaxel, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Nathan Pennell, MD, PhD
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00138203
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)